End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
53.62 EUR | -1.07% | -4.59% | -9.73% |
09:13am | UK Competition Watchdog Begins Probe of Eurofins' Purchase of Technical Testing, Analysis Business | MT |
07-15 | Eurofins: dispute with SGS over termination of contract | CF |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.73% | 10.19B | - | ||
+19.32% | 84.59B | C+ | ||
-21.99% | 77.33B | B- | ||
+0.99% | 27.12B | C+ | ||
-5.06% | 18.19B | B | ||
+7.84% | 18.49B | A- | ||
+7.69% | 16.49B | A- | ||
+76.20% | 13.55B | C- | ||
+76.56% | 13.03B | C+ | ||
-27.72% | 12.43B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ERF Stock
- ESF Stock
- Ratings Eurofins Scientific SE